Alaunos Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-54.3M | $-165.3M | $-120.1M | $-31.8M | $-57.1M | $-96.1M | $-63.8M | $-32.7M |
| Depreciation & Amortization | — | $290.0K | $357.0K | $462.0K | $738.0K | $658.0K | $268.0K | $188.0K |
| Depreciation | $369.0K | $290.0K | $357.0K | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $8.5M | $8.5M | $8.0M | $4.7M | $3.5M | $4.9M | $2.8M | $3.6M |
| Net Cash from Operating Activities | $-54.7M | $-58.3M | $-10.0K | $-36.7M | $-59.5M | $-78.8M | $-38.8M | $-19.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $737.0K | $551.0K | $412.0K | $193.0K | $132.0K | $1.6M | $1.2M | $186.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-737.0K | $-551.0K | — | — | $-131.0K | $-1.6M | $-1.2M | $-186.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $0 | $2.0K | $34.0K | $544.0K | $498.0K | $546.0K | $274.0K | $1.7M |
| Net Cash from Financing Activities | $45.3M | $-788.0K | — | — | $54.5M | $49.0M | $84.3M | $31.4M |
| Net Change in Cash | $-10.1M | $-59.7M | $97.9M | $-25.4M | $-5.1M | $-31.4M | $44.3M | $11.6M |
| Free Cash Flow | $-55.4M | $-58.9M | $-422.0K | $-36.8M | $-59.6M | $-80.4M | $-40.0M | $-19.9M |